Moclobemide (Ro 111163) is a reversible monoamine oxidase A (MAO-A) inhibitor that can cross the blood-brain barrier, with an IC50 value of 6.061μM for hMAO-A[1]. Moclobemide is a classic antidepressant that increases the levels of brain monoamines (such as serotonin, norepinephrine, and dopamine)[2, 3]. Moclobemide can be used to treat mental illnesses such as social anxiety disorder[4].
In vitro, treatment of hypoxic or glutamate-stimulated neuron-astrocyte co-cultures with Moclobemide (10-100µM) significantly increased the number of surviving neurons[5]. Treatment of mixed glial cell cultures with Moclobemide (10-8-100µM) significantly inhibited the LPS-induced increase in TNF-α, IL-1β, and IL-10 mRNA levels in mixed glial cell cultures[6].
In vivo, treatment of chronically stressed mice with Moclobemide (40mg/kg) via intraperitoneal injection significantly increased the number of BrdU-positive cells in the subgranular zone of the hippocampus, upregulated hippocampal progenitor cell proliferation, and reversed the stress-induced decrease in brain-derived neurotrophic factor (BDNF) levels in the hippocampus of mice[7].
References:
[1] Can NÖ, Osmaniye D, Levent S, Sağlık BN, İnci B, Ilgın S, Özkay Y, Kaplancıklı ZA. Synthesis of New Hydrazone Derivatives for MAO Enzymes Inhibitory Activity. Molecules. 2017 Aug 20;22(8):1381.
[2] Fitton, Andrew, Diana Faulds, and Karen L. Goa. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43.4 (1992): 561-596.
[3] Haefely, W., et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology 106.Suppl 1 (1992): S6-S14.
[4] Nutt, D., and S. A. Montgomery. Moclobemide in the treatment of social phobia. International clinical psychopharmacology 11 (1996): 77-82.
[5] Verleye M, Steinschneider R, Bernard F X, et al. Moclobemide attenuates anoxia and glutamate-induced neuronal damage in vitro independently of interaction with glutamate receptor subtypes[J]. Brain research, 2007, 1138: 30-38.
[6] Bielecka A M, Paul-Samojedny M, Obuchowicz E. Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture[J]. Naunyn-Schmiedeberg's archives of pharmacology, 2010, 382(5): 409-417.
[7] Li YF, Zhang YZ, Liu YQ, Wang HL, Yuan L, Luo ZP. Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice. Acta Pharmacol Sin. 2004 Nov;25(11):1408-12. PMID: 15525460.
Moclobemide (Ro 111163)是一种可透过血脑屏障的可逆的单胺氧化酶A(MAO-A)抑制剂,对hMAO-A的IC50值为6.061μM[1]。Moclobemide是经典的抗抑郁药,能提高脑单胺(如5-羟色胺受体、去甲肾上腺素、多巴胺)的水平[2, 3]。Moclobemide能够用于社交焦虑障碍等精神疾病的治疗[4]。
在体外,Moclobemide(10-100µM)处理缺氧或谷氨酸刺激的神经-星体胶质培养物,显著增加了存活神经元的数量[5]。Moclobemide(10-8-100µM)处理混合神经胶质细胞培养物,显著抑制了LPS诱导的混合神经胶质细胞培养物中TNF-α、IL-1β和IL-10 mRNA的水平升高[6]。
在体内,Moclobemide(40mg/kg)通过腹腔注射治疗慢性应激小鼠,显著增加了小鼠海马体颗粒下区的BrdU阳性细胞数量,上调了海马祖细胞的增殖,逆转了应激造成的小鼠海马体内脑源性神经营养因子(BDNF)水平的降低[7]。
















